Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

The company launched several new products, including the NovaSeq X series. Illumina is focusing on expansion in multiomics and data services. Illumina's performance in Q4 2024 showed modest growth ...

The stock declined by 4.33% in after-hours trading, closing at $117.48. The company launched several new products, including the NovaSeq X series. Illumina is focusing on expansion in multiomics and ...

TD Cowen downgraded Illumina Inc (NASDAQ:ILMN) to "Hold" following the company's fourth-quarter earnings, citing weaker-than-expected next-generation sequencing (NGS) consumable growth, increasing ...

The Illumina MiSeq i100 Series, announced last fall ... and building what the company calls“universal software”-meaning that the MiSeq i100 and NovaSeq X leverage many of the same software components, ...

The Illumina MiSeq i100 Series, announced last fall ... company calls "universal software"-meaning that the MiSeq i100 and NovaSeq X leverage many of the same software components, even though ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell ...